Trial Profile
A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2022
Price :
$35
*
At a glance
- Drugs Tazemetostat (Primary)
- Indications Malignant-mesothelioma; Mesothelioma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Epizyme
- 16 May 2022 Results assessing anti-tumour activity and safety of tazemetostat in patients with measurable relapsed or refractory malignant pleural mesothelioma published in the Lancet Oncology
- 21 Sep 2020 Results of integrated safety analysis of tazemetostat using compiled data from 6 trials (NCT01897571, NCT03010982, NCT03028103, NCT02601950, NCT02860286, NCT02875548) presented at the 45th European Society for Medical Oncology Congress
- 31 May 2020 Results evaluated the safety and efficacy of tazemetostat relapsed/refractory (R/R) malignant mesothelioma patients, presented at the 56th Annual Meeting of the American Society of Clinical Oncology